鄧旭坤：中南民族大學(xué)藥學(xué)院教授，博士，碩士生導(dǎo)師。武漢仁旭生物科技有限公司董事長(zhǎng)。中國(guó)藥文化研究會(huì)水療康養(yǎng)分會(huì)副會(huì)長(zhǎng)；世界中醫(yī)藥聯(lián)合會(huì)中藥飲片專委會(huì)常務(wù)理事；中國(guó)國(guó)家南藥科技創(chuàng)新聯(lián)盟副理事長(zhǎng)（單位）；中華中醫(yī)藥學(xué)會(huì)中藥鑒定分會(huì)常務(wù)委員；中國(guó)醫(yī)藥物資協(xié)會(huì)道地藥材分會(huì)常務(wù)理事；中國(guó)民族醫(yī)藥學(xué)（協(xié)）會(huì)科普分會(huì)常務(wù)理事；中國(guó)中醫(yī)藥信息學(xué)會(huì)科技創(chuàng)新與成果轉(zhuǎn)化分會(huì)常務(wù)理事；湖北省實(shí)驗(yàn)動(dòng)物學(xué)會(huì)常務(wù)理事，湖北省毒理學(xué)會(huì)常務(wù)理事；湖北省藥理學(xué)會(huì)常務(wù)理事。主持和參與了國(guó)家自然基金項(xiàng)目5項(xiàng)，科技部科技攻關(guān)計(jì)劃子課題3項(xiàng)，國(guó)家及省部級(jí)課題10余項(xiàng)；先后獲得各類科研經(jīng)費(fèi)共計(jì)約600余萬(wàn)元，與深圳正陽(yáng)生物科技公司、湖北凌晟制藥有限公司、江西康熊控股實(shí)業(yè)集團(tuán)、撫州中諾藥業(yè)有限公司、大灣區(qū)大健康國(guó)際創(chuàng)新研究院、香港中艾國(guó)際集團(tuán)公司、資溪康仁堂生物開(kāi)發(fā)公司等國(guó)內(nèi)知名企業(yè)進(jìn)行深度合作，為企業(yè)和社會(huì)帶來(lái)經(jīng)濟(jì)效益2000余萬(wàn)元。香港“求實(shí)”獎(jiǎng)學(xué)金獲得者，獲得教育部高等學(xué)�？茖W(xué)研究?jī)?yōu)秀成果（科學(xué)技術(shù)）自然科學(xué)獎(jiǎng)二等獎(jiǎng)（2019年），中國(guó)產(chǎn)學(xué)研促進(jìn)會(huì)創(chuàng)新成果優(yōu)秀獎(jiǎng)（2019年），世界中醫(yī)藥聯(lián)合會(huì)中醫(yī)藥國(guó)際貢獻(xiàn)獎(jiǎng)-科學(xué)進(jìn)步二等獎(jiǎng)（2020年）等獎(jiǎng)勵(lì)；發(fā)表90余篇學(xué)術(shù)論文（其中SCI收錄20余篇）；申請(qǐng)國(guó)家發(fā)明專利14項(xiàng)，并獲得6項(xiàng)授權(quán)。參編《中國(guó)毒性民族藥志》、《藥理學(xué)實(shí)驗(yàn)與指導(dǎo)》、《藥劑學(xué)》等教材與專著6部。近年來(lái)積極參與了國(guó)家精準(zhǔn)扶貧計(jì)劃和國(guó)家“一帶一路”國(guó)際傳統(tǒng)醫(yī)藥國(guó)際合作工程，是云南省墨江縣哈尼族醫(yī)藥研究的終生首席顧問(wèn)以及湖北省巴東和長(zhǎng)陽(yáng)兩縣中醫(yī)藥發(fā)展的專家組成員，為2018年“一帶一路”世界傳統(tǒng)醫(yī)藥戰(zhàn)略合作聯(lián)盟“武漢宣言”的主要起草和倡議人之一。目前已經(jīng)與國(guó)內(nèi)二十多所高校和研究機(jī)構(gòu)合作，正在籌建中國(guó)膽汁藥物科技創(chuàng)新研究院和“一帶一路”國(guó)際傳統(tǒng)醫(yī)藥戰(zhàn)略合作聯(lián)盟實(shí)驗(yàn)室。

Xukun Deng(PhD), professor and master supervisor of School of Pharmacy, South-Central University for Nationalities.  and chairman of Wuhan Renxu Biological Technology Co., Ltd.

Vice president of Hydrotherapy Nutrition Association of China Pharmaceutical Culture Society; Standing director of the Chinese Medicine Decoction Pieces Special Committee of the World Federation of Chinese Medicine;Vice President of Chinese National Alliance for Science and Technology Innovation of Southern Medicine (Unit) ，Standing member of Chinese Medicine Identification Branch of China Association of Traditional Chinese Medicine; Standing director of the authentic Chinese medicinal materials association; Executive director of Science and Technology Innovation and Achievement Transformation Branch of China Information Society of Traditional Chinese Medicine; Standing director of the Science Popularizing Branch of the Chinese Association of Ethnic Medicine (Association), standing director of Hubei Experimental Animal Society, standing director of Hubei Toxicology Society;Director of Hubei Pharmacology Society.He has presided over and participated in 5 projects of the National Natural Science Foundation of China, 3 sub-projects of the Science and Technology Research Program of the Ministry of Science and Technology, and more than 10 national and provincial projects.It has obtained various scientific research funds totaling about 6 million yuan. It has carried out in-depth cooperation with well-known domestic enterprises such as Shenzhen Zhengyang Biotechnology Co. LTD， Hubei Lingsheng Pharmaceutical Co. Ltd.,Jiangxi Kang Bear Holding Industry Group, Zixi Zhongnuo Pharmaceutical Co., Ltd.,Greater Bay Area Big Health International Innovation InstituteHong Kong Zhongai International Group Co Fuzhou Kang Ren Tang Biological Development  Co., Ltd., and brought economic benefits of more than ¥20 million yuan to enterprises and the society.Hong Kong "Truth-seeking" scholarship winner, the Ministry of Education of Higher Education Scientific Research Achievements (Science and Technology) Natural Science Award Second Prize(2019), China Association for the Promotion of Industry, Education and Research Outstanding Innovation Achievements Award(2019)，World Federation of Traditional Chinese Medicine International Contribution Award - Scientific Progress Second Prize (2020)and other awards; More than 80 academic papers have been published (more than 20 of them are included in SCI).We have applied for 12 national invention patents and obtained 5 authorization. Participated in compiling 6 textbooks and monographs, such as "Chinese Journal of Toxic Ethnomedicine", "Pharmacological Experiment and Guidance", "Pharmacy", etc.

In recent years, he has actively participated in the national targeted poverty alleviation plan and the national "One Belt And One Road" international traditional medicine international cooperation project, and he is the lifelong chief consultant of Hani medical research in Mojiang County, Yunnan Province, and a member of the expert group on the development of TCM in Badong and Changyang County, Hubei Province,  and one of the main drafters and initiators of the Wuhan Declaration of "One Belt And One Road" of the world traditional medicine strategic cooperation alliance in 2018.

At present, it has cooperated with more than 20 domestic universities and research institutions, and is preparing to build Chinese Bile Medicine Science and Technology Innovation Institute and the "One Belt And One Road" international traditional medicine strategic cooperation alliance laboratory.

近三年發(fā)表的代表性論文：

2021年：

Chenxi Dai, Arslan Yusuf, Hui Sun, Guangwen Shu, Xukun Deng*. A characterized saponin extract of Panax japonicus suppresses hepatocyte EMT and HSC activation in vitro and CCl4-provoked liver fibrosis in mice: Roles of its modulatory effects on the Akt/GSK3 beta/Nrf2 cascade. PHYTOMEDICINE. doi: 10.1016/j.phymed.2021.153746

Guangwen Shu, Arslan Yusuf, Chenxi Dai, Hui Sun, Xukun Deng*. Piperine inhibits AML-12 hepatocyte EMT and LX-2 HSC activation and alleviates mouse liver fibrosis provoked by CCl 4: roles in the activation of the Nrf2 cascade and subsequent suppression of the TGF-β1/Smad axis. FOOD & FUNCTION.2021. doi: 10.1039/d1fo02657g

2020年：

Yongshen Ren, Jiao Ai, Xinqiao Liu, Shuai Liang, Yao Zheng, Xin Deng, Yan Li, Jing Wang, Xukun Deng, Lin-Lin Chen. Anticoagulant active ingredients identification of total saponin extraction of different Panax medicinal plants based on grey relational analysis combined with UPLC-MS and molecular docking. JOURNAL OF ETHNOPHARMACOLOGY. doi: 10.1016/j.jep.2020.112955

YongShen Ren, Yao Zheng, Huan Duan, Lei Lei, Xin Deng, XinQiao Liu, ZhiNan Mei, XuKun Deng*. Dandelion polyphenols protect against acetaminophen-induced hepatotoxicity in mice via activation of the Nrf-2/HO-1 pathway and inhibition of the JNK signaling pathway. CHINESE JOURNAL OF NATURAL MEDICINES. doi: 10.1016/S1875-5364(20)30011-X

舒廣文, 阿爾斯拉•玉蘇甫, 邱韻涵, 戴晨曦, 鄧旭坤*. 維吾爾藥復(fù)方待比地力對(duì)順鉑所致小鼠腎損傷的保護(hù)作用[J].中南民族大學(xué)學(xué)報(bào)(自然科學(xué)版),2020,39(05):478-482.

徐瑞, 劉釗, 付千, 段歡, 鄧旭坤*.竹節(jié)參多糖對(duì)對(duì)乙酰氨基酚誘導(dǎo)的小鼠肝損傷的保護(hù)作用[J].中南民族大學(xué)學(xué)報(bào)(自然科學(xué)版),2020,39(01):51-55.

鄧鑫, 任永申, 雷蕾, 鄭堯, 李燕, 廖矛川, 鄧旭坤*, 張萍. 復(fù)方竹節(jié)參顆粒對(duì)縮宮素誘導(dǎo)的原發(fā)性痛經(jīng)的影響[J].中成藥,2020,42(01):55-61.

2019年：

Guangwen Shu, Yunhan Qiu, Ji Hao, Qian Fu, Xukun Deng*, Nuciferine alleviates acute alcohol-induced liver injury in mice: Roles of suppressing hepatic oxidative stress and inflammation via modulating miR-144/Nrf2/HO-1 cascade. JOURNAL OF FUNCTIONAL FOODS.doi 10.1016/j.jff.2019.04.055

Guangwen Shu, Yunhan Qiu, Ji Hao, Qian Fu, Xukun Deng*, gamma-Oryzanol alleviates acetaminophen-induced liver injury: roles of modulating AMPK/GSK3 beta/Nrf2 and NF-kappa B signaling pathways. FOOD & FUNCTION.doi 10.1039/c9fo01808e

舒廣文, 邱韻涵, 付千, 段歡, 余惠凡, 鄧旭坤*.桑葚總多糖對(duì)對(duì)乙酰氨基酚誘導(dǎo)小鼠急性肝損傷的保護(hù)作用[J].中南民族大學(xué)學(xué)報(bào)(自然科學(xué)版),2019,38(03):377-382.

鄧旭坤, 余惠凡, 劉釗, 舒廣文, 鄭燕, 段歡. 綿萆薢化學(xué)成分研究(Ⅱ)[J].中南民族大學(xué)學(xué)報(bào)(自然科學(xué)版),2019,38(03):411-414.

黃旭, 郝吉, 李薇, 蔡夢(mèng)珊, 鄧旭坤*, 舒廣文. 石榴籽油對(duì)D-半乳糖誘導(dǎo)衰老小鼠免疫功能的調(diào)節(jié)作用[J]. 中國(guó)食品學(xué)報(bào). 2019,19(07)

鄧旭坤, 付千, 舒廣文, 鄭燕, 徐瑞, 邱韻涵, 段歡, 余惠凡. 鞣花酸對(duì)順鉑引起小鼠急性腎損傷的影響[J]. 中南民族大學(xué)學(xué)報(bào)(自然科學(xué)版). 2019,38(02)

付千, 徐瑞, 段歡, 余惠凡, 邱韻涵, 舒廣文, 鄧旭坤*. 刺山柑乙酸乙酯部位對(duì)APAP誘導(dǎo)肝損傷的保護(hù)作用及體外抗氧化活性測(cè)定[J]. 時(shí)珍國(guó)醫(yī)國(guó)藥, 2019, 30(03): 520-523.

2018年：

Guangwen Shu, Shanqing Jiang, Jun Mu, Huifan Yu, Huan Duan, Xukun Deng*, Antitumor immunostimulatory activity of polysaccharides from Panax japonicus C. A. Mey: Roles of their effects on CD4+T cells and tumor associated macrophages. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. doi 10.1016/j.ijbiomac.2018.01.011

Wei Li, Yunhan Qiu, Ji Hao, Chi Zhao, Xukun Deng*, Guangwen Shu,Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.FOOD AND CHEMICAL TOXICOLOGY.doi 10.1016/j.fct.2018.08.030

Zhenpeng Qiu, Cong Zhang, Junxuan Zhou, Junjie Hu, Lei Sheng, Xin Li, Liang Chen, Xiang Li, Xukun Deng, Guohua Zheng,Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. MOLECULAR CARCINOGENESIS.doi 10.1002/mc.22904

李薇, 郝吉, 張浪, 黃旭, 鄧旭坤, 舒廣文. 石榴籽油在D-半乳糖誘導(dǎo)的衰老小鼠體內(nèi)的抗氧化作用[J]. 中國(guó)油脂, 2018, 43(02): 55-59+64.

舒廣文, 邱韻涵, 李薇, 付千, 諶業(yè)珺, 鄧旭坤*. 荷葉總生物堿激活肝臟AMPK/Nrf2通路緩解對(duì)乙酰氨基酚誘導(dǎo)的小鼠急性肝損傷[J]. 天然產(chǎn)物研究與開(kāi)發(fā). 2019, 31(02): 198-203

鄧旭坤*, 段歡, 劉釗, 舒廣文, 江善青, 余惠凡. 黃精多糖對(duì)環(huán)磷酰胺誘導(dǎo)小鼠免疫抑制的影響[J]. 中南民族大學(xué)學(xué)報(bào)(自然科學(xué)版). 2018,37(02): 49-53.